# Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma

> **NCT05842707** · PHASE1,PHASE2 · RECRUITING · sponsor: **Aibin Liang，MD，Ph.D.** · enrollment: 48 (estimated)

## Conditions studied

- Refractory or Relapsed B-cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** dualCAR-NK19/70 cell

## Key facts

- **NCT ID:** NCT05842707
- **Lead sponsor:** Aibin Liang，MD，Ph.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-18
- **Primary completion:** 2028-01-18
- **Final completion:** 2029-01-18
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05842707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05842707, "Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05842707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*